Financial Data and Key Metrics Changes - Global sales for the second quarter were $3.2 billion, reflecting a sales growth of 3.3% compared to 2024, with constant currency sales growing by 2.7% [24][25] - GAAP operating margin for 2025 was 4.67%, a decrease of 42 basis points year-over-year, while non-GAAP operating margin was 6.96%, down 79 basis points [25][26] - GAAP net income for the second quarter was $86 million or $0.70 per diluted share, compared to $104 million or $0.80 per diluted share in the prior year [26][27] Business Line Data and Key Metrics Changes - U.S. Dental merchandise sales declined by 1.2% due to increased volume offset by lower product pricing, while U.S. Dental equipment sales fell by 4.7% due to economic uncertainty [28][29] - U.S. Medical Distribution business sales grew by 6.3%, driven by increased patient traffic and strong performance in the Home Solutions business [29] - Global Specialty Products Group sales grew by 4.2%, with solid growth in the implant and biomaterial business, including double-digit growth in value implants [30][31] Market Data and Key Metrics Changes - International Dental merchandise sales grew by 1.9%, impacted by the timing of Easter, while international Dental equipment sales grew by 12.1%, driven by strong sales in Canada and Europe [29][30] - The U.S. Dental market growth is still impacted by staffing challenges, but practice productivity is increasing as dentists invest in devices [48][49] - Patient traffic in the dental distribution business is reported to be stable globally, with some regions showing positive trends [46][51] Company Strategy and Development Direction - The company is maintaining its full-year guidance, expecting earnings to be weighted towards the second half of the year, aiming for high single-digit to low double-digit earnings growth [7][39] - The company is partnering with KKR's Capstone and engaging global management consulting firms to enhance distribution gross margins and increase efficiencies [7][8] - The Bold plus One strategy is being advanced, focusing on customer satisfaction and financial goals [8][23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to high single-digit to low double-digit earnings growth, supported by strong July sales and targeted sales initiatives [39][40] - The company is confident in the stability of patient traffic and the potential for growth in the second half of the year, particularly in the dental equipment sector [66][67] - Management acknowledged macroeconomic uncertainties but remains positive about the overall market conditions and growth opportunities [66][67] Other Important Information - The company expects to achieve annual run rate savings of over $100 million by the end of 2025 from restructuring efforts [33][34] - The company repurchased approximately 3.7 million shares of common stock at an average price of $70.88 per share during 2025 [34][35] - The CEO announced plans to retire at the end of the year, transitioning to the role of Chairman of the Board [21][22] Q&A Session Summary Question: Can you provide insights on the dental business and patient traffic? - Management reported positive trends in July sales, with stable patient traffic and confidence in sustaining these trends moving forward [46][49] Question: What is the current state of the engagement with consulting firms? - The company is focusing on gross profit enhancement and restructuring, with expectations for positive results in 2026 [55][59] Question: How should we think about EPS cadence in the second half of the year? - EPS is expected to grow in the third quarter, with further growth anticipated in the fourth quarter, supported by targeted sales initiatives [65][66] Question: Can you comment on the orthodontic business and its turnaround? - The orthodontic business is small but showing signs of improvement, with efforts to stabilize and enhance profitability [70][73] Question: What is the outlook for DSOs and new office design projects? - DSOs are generally moving in a positive direction, with funding available for expansion and consistent growth in new office design projects [80][83]

Financial Performance - Q2 2025 - Total sales increased by 3.3% to $3.24 billion[18, 54], with constant currency growth of 2.7%[15, 19, 22] - Non-GAAP diluted EPS was $1.10, a decrease of 10.6% compared to $1.23 in Q2 2024[15, 18, 54] - Adjusted EBITDA was $256 million, a decrease of 4.8% compared to $268 million in Q2 2024[15, 18, 57] - Global Distribution and Value-Added Services Group sales grew by 2.4% in constant currency[15, 22] - Global Specialty Products Group sales grew by 3.3%[15, 22] - Global Technology Group sales grew by 6.6%[15, 22] Segment Performance - U S dental merchandise sales decreased 1.2%[22] - International dental merchandise constant currency sales grew 0.5%[22] - U S Medical sales grew 6.3% including acquisitions[22] Guidance and Strategy - The company maintains 2025 non-GAAP diluted EPS guidance of $4.80 to $4.94[12, 46, 48] - 2025 Adjusted EBITDA is expected to grow in the mid-single digits versus 2024 Adjusted EBITDA of $1.1 billion[46] - Total sales growth for 2025 is projected to be between 2% and 4%[12, 48]

Core Viewpoint - ZimVie Inc. reported its financial results for the second quarter of 2025, showing a slight decline in net sales but an improvement in net loss compared to the previous year. The company is also in the process of being acquired by an affiliate of ARCHIMED for $19.00 per share, which will take ZimVie private and remove its shares from NASDAQ trading. Financial Performance - Net sales for Q2 2025 were $116.7 million, a decrease of 0.1% on a reported basis and 2.1% in constant currency compared to Q2 2024 [2][3] - The net loss for Q2 2025 was $(3.8) million, an improvement of $5.7 million from a net loss of $(9.6) million in Q2 2024 [3][9] - The net loss margin for Q2 2025 was (3.3%), improving by 490 basis points from (8.2%) in Q2 2024 [3][4] - Adjusted net income for Q2 2025 was $7.2 million, an increase of $3.6 million from Q2 2024 [3][4] Earnings Per Share - Basic and diluted EPS for Q2 2025 were $(0.14), while adjusted diluted EPS was $0.26 [4][9] Adjusted EBITDA - Adjusted EBITDA for Q2 2025 was $17.5 million, representing 15.0% of net sales, an increase of $1.6 million or 150 basis points from Q2 2024 [4][9] Acquisition Details - On July 21, 2025, ZimVie announced a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 in cash per share [6][7] - The transaction is expected to close by year-end 2025, pending stockholder approval and regulatory approvals [7][9] Company Overview - ZimVie is a global leader in the dental implant market, focusing on developing and delivering products for dental tooth replacement and restoration [9][10]

Core Points - ZimVie Inc. will report its financial results for Q2 2025 on July 30, 2025, after market close [1] - ZimVie has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash [2] - The acquisition is expected to close by the end of 2025, pending stockholder and regulatory approvals [3] Company Overview - ZimVie is a global leader in the dental implant market, focusing on developing and delivering products for dental tooth replacement and restoration [4] - The company aims to enhance smiles, function, and confidence through its comprehensive portfolio, which includes dental implants, biomaterials, and digital workflow solutions [4] Transaction Details - Upon completion of the acquisition, ZimVie will become a privately held company, and its shares will no longer be traded on NASDAQ [3] - Due to the pending acquisition, ZimVie will not hold a conference call for Q2 and has withdrawn its fiscal 2025 guidance [3]

Core Insights - ZimVie Inc. has entered a strategic distribution agreement with Osstem Implant Co., Ltd. to enhance its presence in the growing Chinese dental implant market, which is estimated to exceed 10 million units annually [1][2] Company Overview - ZimVie is a global leader in the dental implant market, focusing on developing and delivering a comprehensive portfolio of products for dental tooth replacement and restoration [5] - Osstem Implant, founded in 1997, is the largest dental implant manufacturer globally and a leading provider in the Asia-Pacific region, with a strong distribution network in over 90 countries [6] Market Dynamics - The partnership allows ZimVie to leverage Osstem's established distribution channels and clinical training programs, enhancing customer access to ZimVie's innovative implant portfolio [2][4] - Osstem Implant has built a robust presence in over 90 cities in China and conducts nearly 500 clinical training sessions annually, which strengthens its market position [2] Strategic Benefits - The collaboration is expected to provide a wider product selection for dental professionals and patients, enhancing the overall customer experience [4] - ZimVie's premium implants are designed for precision, aesthetics, and durability, aligning with the company's commitment to innovation and global expansion [4]

Core Viewpoint - ZimVie Inc. has entered into a definitive agreement to be acquired by ARCHIMED, an investment firm focused on healthcare industries, for $19.00 per share, representing a 99% premium over its recent trading price, with an enterprise value of approximately $730 million [2][3]. Company Overview - ZimVie is a global leader in the dental implant market, developing and delivering a comprehensive portfolio of products aimed at supporting dental tooth replacement and restoration procedures [8]. - The company is headquartered in Palm Beach Gardens, Florida, and is committed to advancing clinical science and technology in the dental sector [8]. Acquisition Details - Under the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share, with the transaction expected to close by year-end 2025, pending customary closing conditions [2][4]. - The Board of Directors of ZimVie has unanimously approved the transaction, which is not subject to a financing condition [4]. - Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on NASDAQ [5]. Strategic Implications - The acquisition is expected to provide ZimVie with the strategic and financial backing necessary to expand its innovative dental technology globally [3]. - ARCHIMED views ZimVie as having strong fundamentals and compelling growth potential, indicating a positive outlook for the company's future [3]. Go-Shop Period - ZimVie has a 40-day go-shop period during which it can solicit proposals from third parties, ending on August 29, 2025 [6]. - There is no assurance that this solicitation process will yield a superior proposal [6]. Advisory Roles - Centerview Partners is serving as the exclusive financial advisor to ZimVie, while UBS Investment Bank is the exclusive financial advisor to ARCHIMED [7].

Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on life sciences and offering a comprehensive portfolio of products for dental tooth replacement and restoration procedures [2] - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide [2] - ZimVie aims to enhance smiles, function, and confidence through its dental implants, biomaterials, and digital workflow solutions [2] Upcoming Events - ZimVie management will participate in the Stifel 2025 Jaws & Paws Conference, scheduled for May 28, 2025, at 3:00 p.m. Eastern Time [1] - A live webcast and archived recording of the event will be available on ZimVie's investor website [1]

Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on life sciences and offering a comprehensive portfolio of products for dental tooth replacement and restoration procedures [2][3] - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide [2] Financial Results Announcement - ZimVie will report its financial results for the first quarter of 2025 after market close on May 8, 2025 [1] - A conference call will be hosted by company management at 4:30 p.m. Eastern Time on the same day [1] Conference Call Details - Interested participants can register online to listen to the conference call, with a recommendation to register more than 15 minutes before the start [2] - A replay of the webcast will be available on the investor section of ZimVie's website [2]